2614161-13-4
Chemical Structure
MyoMed 205
- CAS No.: 2614161-13-4
- Formula:C26H25N3O5S
- Molecular Weight:491.56
InChIKey: JPPDUCIRFIVCPH-UHFFFAOYSA-N
SMILES: O=C1OC2=C(C(C)=C1)C=CC(OCC3=CC=C(C(NCCNC(NCC4=CC=CS4)=O)=O)C=C3)=C2
Biological Activity: MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MyoMed 205 | 98.10% | MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Adams V, et al. Small-Molecule Chemical Knockdown of MuRF1 in Melanoma Bearing Mice Attenuates Tumor Cachexia Associated Myopathy. Cells. 2020;9(10):2272. Published 2020 Oct 11. [Content Brief]
- [2]. Labeit S, et al. Regulation of Glucose Metabolism by MuRF1 and Treatment of Myopathy in Diabetic Mice with Small Molecules Targeting MuRF1. Int J Mol Sci. 2021;22(4):2225. Published 2021 Feb 23. [Content Brief]
- [3]. Adams V, et al. Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility. J Cachexia Sarcopenia Muscle. 2022;13(3):1565-1581. [Content Brief]
